Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

By M. Zander, S. Madsbad, J. Madsen, Jens J. Holst. The Lancet, 2002

1,366 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. (2004, background): “, reduced glucotoxicity and lowering of free fatty acids (35).”
Incretin-based therapies for type 2 diabetes mellitus (2009, background): “Continuous, subcutaneous administration of native GLP-1 to patients with type 2 diabetes mellitus (T2DM) lowers fasting and postprandial levels of glucose and HbA 1c effectively, and also results in weight loss”
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. (2004, neutral): “(85) employed continuous subcutaneous infusion to investigate the potential of GLP-1 treatment in type 2 diabetes.”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, methodology): “…of GLP-1R-dependent effects on glucose homeostasis in vivo (Klonoff et al., 2008), and an elevated steady state of plasma GLP-1 for 6 to 12 weeks in clinical trials has resulted in effective reduction in blood glucose levels without any loss of potency (Zander et al., 2002; Meneilly et al., 2003).”